Brokerages Set CRISPR Therapeutics AG (NASDAQ:CRSP) Price Target at $74.94

CRISPR Therapeutics AG (NASDAQ:CRSP) has earned a consensus rating of “Hold” from the nineteen analysts that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $74.94.

A number of research analysts have issued reports on the company. Truist Financial lowered their price objective on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Thursday, August 8th. Rodman & Renshaw initiated coverage on shares of CRISPR Therapeutics in a research note on Friday, August 2nd. They set a “buy” rating and a $90.00 price objective for the company. Barclays dropped their target price on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 6th. Finally, Chardan Capital cut their price target on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th.

CRISPR Therapeutics Trading Down 0.5 %

Shares of CRSP stock opened at $51.62 on Friday. The company’s fifty day moving average price is $47.45 and its 200-day moving average price is $52.16. The stock has a market cap of $4.41 billion, a PE ratio of -18.24 and a beta of 1.67. CRISPR Therapeutics has a 12 month low of $43.42 and a 12 month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The business had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same quarter last year, the firm earned ($1.41) earnings per share. On average, sell-side analysts forecast that CRISPR Therapeutics will post -5.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at $2,896,989.16. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares of the company’s stock, valued at $2,896,989.16. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SFE Investment Counsel raised its stake in shares of CRISPR Therapeutics by 3.6% during the second quarter. SFE Investment Counsel now owns 5,846 shares of the company’s stock valued at $316,000 after acquiring an additional 203 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in shares of CRISPR Therapeutics by 4.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock valued at $249,000 after buying an additional 211 shares during the period. Orion Capital Management LLC raised its holdings in shares of CRISPR Therapeutics by 44.0% in the first quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock valued at $49,000 after acquiring an additional 220 shares in the last quarter. National Bank of Canada FI lifted its stake in CRISPR Therapeutics by 35.0% in the second quarter. National Bank of Canada FI now owns 848 shares of the company’s stock worth $46,000 after acquiring an additional 220 shares during the period. Finally, Larson Financial Group LLC grew its holdings in CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after acquiring an additional 276 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.